Search clinical trials for: Myeloma

Total 3755 results

Hebei Senlang Biotechnology Inc., Ltd.
Cangzhou People's Hospital

Recruiting

CAR-T Cells in the Treatment of Malignant Hematological Tumors

Lymphoma, B-Cell | Multiple Myeloma | Leukemia, T-Cell | Leukemia, B-cell

China
Thomas Lund

Recruiting

Home Treatment With Carfilzomib in Patients With Multiple Myeloma

Multiple Myeloma

Denmark
RenJi Hospital

Recruiting

A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma

Insomnia | Psychological Distress | Somatic Symptoms

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma | Acute Lymphoblastic Leukemia

China
University of Rochester
Karyopharm Therapeutics Inc

Recruiting

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
Carevive Systems, Inc.

Recruiting

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring

Breast Cancer | Multiple Myeloma | Lung Cancer | Gastrointestinal Cancer

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (PLYCOM)

Multiple Myeloma

Korea, Republic of, Australia, Spain, France, Poland
Hellenic Society of Hematology
GlaxoSmithKline

Not yet recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Neoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Multiple Myeloma in Relapse | Gammopathy, Monoclonal | Haematologic Disease
Seoul National University Hospital

Recruiting

Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma

Multiple Myeloma

Korea, Republic of
Institute of Hematology & Blood Diseases Hospital
MethylGene Tech Co., Ltd. China

Recruiting

ctDNA Methylation Sequencing for Myeloma

Multiple Myeloma

China
Hellenic Society of Hematology
GlaxoSmithKline

Recruiting

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Neoplasms | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Gammopathy, Monoclonal | Haematologic Disease | Neoplasm, Plasma Cell

Greece
University Hospital, Lille
Janssen Pharmaceutica N.V., Belgium

Not yet recruiting

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (IFM2021-01)

Multiple Myeloma
Janssen Research & Development, LLC

Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

Relapsed or Refractory Multiple Myeloma

United States, Canada, Australia, China, Germany, Belgium, Malaysia, Turkey, Israel, Sweden, Spain, United Kingdom, Czechia, Denmark, Brazil, Italy, France, Japan, Netherlands, Poland, Austria, Portugal, Greece, India
Baxter Healthcare Corporation

Not yet recruiting

Doxil/Caelyx BE Study

Multiple Myeloma | Ovarian Cancer | Metastatic Breast Cancer | AIDS-related Kaposi Sarcoma
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Recruiting

PROFAST Intervention in Precursor Multiple Myeloma (PROFAST)

Multiple Myeloma | Weight Loss | Fasting | MGUS | Cancer Prevention | Smoldering Waldenstrom Macroglobulinemia(WM)

United States
Zhejiang ACEA Pharmaceutical Co. Ltd.

Recruiting

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
National Cancer Institute (NCI)

Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
The First Affiliated Hospital of Soochow University

Not yet recruiting

Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma
GPCR Therapeutics, Inc.

Recruiting

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Multiple Myeloma

United States
Fu chengcheng PhD

Not yet recruiting

Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse

Multiple Myeloma at First Relapse
PETHEMA Foundation
Bristol-Myers Squibb; Sanofi; Adknoma; Start from scratch

Not yet recruiting

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide (GEM21menos65)

Newly Diagnosed Multiple Myeloma

Spain
Bayside Health
Monash University

Recruiting

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Lymphoma, Non-Hodgkin | Multiple Myeloma | HIV | Chronic Lymphocytic Leukemia | Organ Transplantation | COVID-19 Vaccines

Australia
University of Alabama at Birmingham

Recruiting

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry (CARE-Heme)

Multiple Myeloma | Amyloidosis | Plasma Cell Leukemia

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Multiple Myeloma

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related

United States, Puerto Rico
Amsterdam UMC, location VUmc

Not yet recruiting

Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study (POMAlternative)

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
National Cancer Institute (NCI)

Not yet recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Belgium, Korea, Republic of, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Czechia, Brazil, Netherlands, Poland, Switzerland, Norway, Germany
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)

Relapsed or Refractory Multiple Myeloma

United States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
Institute of Hematology & Blood Diseases Hospital

Recruiting

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

China
University Hospital, Caen

Not yet recruiting

Benefits of Adapted Physical Activity for Chronic Osteoarticular Pain in Patients With Multiple Myeloma (ALGOMYELOMOV)

Chronic Pain | Multiple Myeloma | Adapted Physical Activity
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Pharmacosmos A/S

Not yet recruiting

A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation

Multiple Myeloma | Malignant Lymphoma
Institute of Hematology & Blood Diseases Hospital
Shanghai Kuaixu Biotechnology Co., Ltd

Recruiting

Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Multiple Myeloma

China
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)

Multiple Myeloma

United States, Italy, Spain, Australia, Belgium, Israel, Germany, France
The Affiliated People's Hospital of Ningbo University

Recruiting

Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma

China
University of Miami
Karyopharm Therapeutics Inc

Recruiting

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge)

Relapsed and Refractory Multiple Myeloma

United States
Sir Mortimer B. Davis - Jewish General Hospital

Not yet recruiting

Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD (TELO - DMRD)

Multiple Myeloma
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc.

Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Lymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological Malignancies

China
PETHEMA Foundation
Janssen-Cilag, S.A.; Celgene-BMS; LIDESEC

Not yet recruiting

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Multiple Myeloma

Spain
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Celgene

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

Relapsed or Refractory Multiple Myeloma

United States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
Affiliated Hospital to Academy of Military Medical...

Recruiting

High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma

Multiple Myeloma

China
University of Southern California
National Cancer Institute (NCI)

Recruiting

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Samsung Medical Center

Recruiting

Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone (KMM2002)

Multiple Myeloma

Korea, Republic of
Xuzhou Medical University

Recruiting

Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)

Multiple Myeloma

China
Jose Pablo Leone
Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC)

Recruiting

ETHAN - ET for Male BC

Male Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Negative Breast Carcinoma

United States

Search clinical trials for: Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations